Physician profile
Paul Smith
NPI 1659530434
$2,981.74
in general payments reported to CMS, 2019-2025
23 companies · $652 in 2025
The $652 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $68.98 · 2021: $267 · 2022: $206 · 2023: $849 · 2024: $226 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143 · Travel and Lodging: $584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.19 |
| Travel and Lodging | $583.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $893.87 | 2019-2025 | Axonics, Rezum Generator, Moses 550 D\F\L |
| Astellas Pharma US INC | $369.20 | 2019-2025 | Myrbetriq, Padcev, Xtandi |
| Abbvie INC. | $268.72 | 2019-2025 | |
| Teleflex LLC | $248.68 | 2025 | Urolift, Barrigel |
| Sumitomo Pharma America, INC. | $211.01 | 2023-2025 | Gemtesa |
| C. R. Bard, INC. & Subsidiaries | $131.22 | 2019 | |
| Endo Pharmaceuticals INC. | $103.81 | 2019-2024 | Aveed, Xiaflex |
| Coloplast Corp | $97.63 | 2022 | |
| Allergan, INC. | $93.36 | 2019-2021 | |
| 180 Medical, INC. | $87.55 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $81.80 | 2023-2025 | Prolaris |
| Endo USA, INC. | $75.76 | 2024-2025 | Xiaflex, Aveed |
| Olympus America INC. | $74.26 | 2023-2025 | Itind System, Soltive |
| Pfizer INC. | $52.30 | 2019-2022 | |
| Medtronic, INC. | $41.69 | 2023-2025 | Signia, Polysorb |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $25.12 | 2024 | |
| Axonics, INC. | $25.09 | 2023 | Axonics |
| Tolmar, INC. | $20.29 | 2025 | Eligard, Jatenzo |
| Convatec INC. | $19.97 | 2019 | |
| Therapeuticsmd, INC. | $18.76 | 2019 | |
| Amgen INC. | $14.61 | 2020 | |
| Antares Pharma, INC. | $13.86 | 2024 | Xyosted |
| Urovant Sciences INC | $13.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.